ALPHAEON and Zelegent Announce Exclusive Global Agreement to Commercialize Office-Based Snoring Therapy

IRVINE, Calif., Dec. 15, 2015 /PRNewswire/ — ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Zelegent, Inc. jointly announced today that the two companies have entered into an exclusive worldwide agreement to bring Zelegent’s office-based Elevoplasty technology to board certified sleep specialists.  Under the terms of the agreement, which includes product development and commercialization, ALPHAEON became the lead investor in Zelegent’s Series A Financing. The amount of the investment was not disclosed.  

Read more here

Zelegent is part of the EvoNexus Irvine portfolio.